Gimv and EGS Beteiligungen reinforce strategic support for SpineArt with CHF 25m capital increase to accelerate global growth

Niederer Kraft Frey advised SpineArt in the transaction.

Spineart, a global medtech innovator in advanced spine surgery solutions, has raised CHF 25 million in a capital increase backed by its long-standing investors Gimv and EGS Beteiligungen (EGSB). This new funding will fuel Spineart’s next phase of profitable growth, enabling the company to advance its innovation pipeline and strengthen its global footprint in delivering better outcomes for spine surgery patients.

Spineart’s profitable growth strategy is anchored in a comprehensive portfolio of cutting-edge technologies designed to make spine surgery safer, more efficient and more effective. With a strong focus on clinical outcomes, the company is expanding across Europe and the United States with ongoing regulatory submissions to the U.S. FDA for its BAGUERA® C cervical disc prosthesis. Strategic partnerships and investments in digital navigation and robotics are also enhancing Spineart’s innovation capabilities, adding a transformative dimension to its future growth.

Spineart currently employs over 360 professionals worldwide and is projected to reach revenues of approximately EUR 140 million in 2025, reflecting five consecutive years of growth at an average annual rate of +16%. With a recently opened modern production facility in Reignier, France, the company is well-positioned to meet the rising global demand for its advanced spine surgery solutions.

The NKF team was led by Corporate/M&A partner Jacques Bonvin, working with partner Andrea Wuerzner (Corporate/M&A) and associate Boris Catzeflis (Corporate/M&A and Technology).